[
  {
    "ts": null,
    "headline": "NEW YORK MARKET CLOSE: Tech names fall; PayPal, Novo prints disappoint",
    "summary": "NEW YORK MARKET CLOSE: Tech names fall; PayPal, Novo prints disappoint",
    "url": "https://finnhub.io/api/news?id=a57ba87ea63494f9f5d3266789b35bc0cf44f11c219660edca8ea852cd7f9c74",
    "source": "Fintel",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770154087,
      "headline": "NEW YORK MARKET CLOSE: Tech names fall; PayPal, Novo prints disappoint",
      "id": 138346849,
      "image": "",
      "related": "MRK",
      "source": "Fintel",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=a57ba87ea63494f9f5d3266789b35bc0cf44f11c219660edca8ea852cd7f9c74"
    }
  },
  {
    "ts": null,
    "headline": "Merck & Co Inc (MRK) Q4 2025 Earnings Call Highlights: Strong Growth Amidst Challenges",
    "summary": "Merck & Co Inc (MRK) reports robust oncology growth and strategic acquisitions, despite facing headwinds from generic competition and declining vaccine sales.",
    "url": "https://finnhub.io/api/news?id=8f26216cdce1e8067f2aa4afebd78bc3c2d45bd784355eb5dcd5afedd687022c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770152536,
      "headline": "Merck & Co Inc (MRK) Q4 2025 Earnings Call Highlights: Strong Growth Amidst Challenges",
      "id": 138347185,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck & Co Inc (MRK) reports robust oncology growth and strategic acquisitions, despite facing headwinds from generic competition and declining vaccine sales.",
      "url": "https://finnhub.io/api/news?id=8f26216cdce1e8067f2aa4afebd78bc3c2d45bd784355eb5dcd5afedd687022c"
    }
  },
  {
    "ts": null,
    "headline": "MSD’s 2026 sales forecast falls short amid patent losses despite strong Q4",
    "summary": "Eyes are firmly on the drugmaker’s future revenue streams amid Keytruda’s looming patent expiry.",
    "url": "https://finnhub.io/api/news?id=62df32d41cf1d69e90c1f201b93c90bb8d673906d63cb80f90f40e9ba1887e87",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770140451,
      "headline": "MSD’s 2026 sales forecast falls short amid patent losses despite strong Q4",
      "id": 138344133,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Eyes are firmly on the drugmaker’s future revenue streams amid Keytruda’s looming patent expiry.",
      "url": "https://finnhub.io/api/news?id=62df32d41cf1d69e90c1f201b93c90bb8d673906d63cb80f90f40e9ba1887e87"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Stock Falls After Solid Earnings. What’s Troubling Wall Street.",
    "summary": "Pfizer also releases positive top-line results from a trial for its injectable GLP-1 receptor agonist in adults with obesity.",
    "url": "https://finnhub.io/api/news?id=3832aa262b018c21df2084ae086538ca8e2b17cf52cdc851cda9f65af35475e1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770126600,
      "headline": "Pfizer Stock Falls After Solid Earnings. What’s Troubling Wall Street.",
      "id": 138341732,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Pfizer also releases positive top-line results from a trial for its injectable GLP-1 receptor agonist in adults with obesity.",
      "url": "https://finnhub.io/api/news?id=3832aa262b018c21df2084ae086538ca8e2b17cf52cdc851cda9f65af35475e1"
    }
  },
  {
    "ts": null,
    "headline": "Dow Hits Record, Nasdaq Sinks as Tech Stocks Retreat",
    "summary": "Nvidia and Microsoft Slide, Palantir Surges on Strong Q4 Earnings",
    "url": "https://finnhub.io/api/news?id=e1257a96afb9f3730646328307c04196b8e3a239da223c32cdd1ed7d5d6505dc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770139809,
      "headline": "Dow Hits Record, Nasdaq Sinks as Tech Stocks Retreat",
      "id": 138343975,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Nvidia and Microsoft Slide, Palantir Surges on Strong Q4 Earnings",
      "url": "https://finnhub.io/api/news?id=e1257a96afb9f3730646328307c04196b8e3a239da223c32cdd1ed7d5d6505dc"
    }
  },
  {
    "ts": null,
    "headline": "Merck 2026 Outlook Misses as Gardasil Sales Drop 35%",
    "summary": "Merck forecasts $65.5--$67 billion in 2026 sales, excluding China Gardasil shipments, despite stronger results from newer medicines.",
    "url": "https://finnhub.io/api/news?id=72c0b181be8d11c69e7b9757d3c00afd8572c6a89bb0f3bc8bc83fd2dab0f2e9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770139131,
      "headline": "Merck 2026 Outlook Misses as Gardasil Sales Drop 35%",
      "id": 138344135,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck forecasts $65.5--$67 billion in 2026 sales, excluding China Gardasil shipments, despite stronger results from newer medicines.",
      "url": "https://finnhub.io/api/news?id=72c0b181be8d11c69e7b9757d3c00afd8572c6a89bb0f3bc8bc83fd2dab0f2e9"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Fourth-Quarter Earnings Unexpectedly Rise; COVID-19 Product Sales Plunge",
    "summary": "Pfizer's (PFE) fourth-quarter earnings unexpectedly increased year over year, although the pharmaceu",
    "url": "https://finnhub.io/api/news?id=eaf3b0320346d4f9af0f8bbf540845a0aa1ac9a6ea70b6e423a04c3c6df20fb4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770138907,
      "headline": "Pfizer Fourth-Quarter Earnings Unexpectedly Rise; COVID-19 Product Sales Plunge",
      "id": 138344070,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Pfizer's (PFE) fourth-quarter earnings unexpectedly increased year over year, although the pharmaceu",
      "url": "https://finnhub.io/api/news?id=eaf3b0320346d4f9af0f8bbf540845a0aa1ac9a6ea70b6e423a04c3c6df20fb4"
    }
  },
  {
    "ts": null,
    "headline": "Top Midday Stories: PayPal Misses Q4 Estimates, Names CEO; Palantir Shares Rise on Strong Results",
    "summary": "US benchmark stock indexes fell in late-morning trading Tuesday as investors weighed earnings from m",
    "url": "https://finnhub.io/api/news?id=0888a5e63c2bc01e9bb9169b8905c0be0c52d5c10800919507ec57cf2ffec643",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770136850,
      "headline": "Top Midday Stories: PayPal Misses Q4 Estimates, Names CEO; Palantir Shares Rise on Strong Results",
      "id": 138344108,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "US benchmark stock indexes fell in late-morning trading Tuesday as investors weighed earnings from m",
      "url": "https://finnhub.io/api/news?id=0888a5e63c2bc01e9bb9169b8905c0be0c52d5c10800919507ec57cf2ffec643"
    }
  },
  {
    "ts": null,
    "headline": "Will Reblozyl Shine in Bristol Myers' Fourth-Quarter Results?",
    "summary": "BMY leans on fast-growing Reblozyl, now a $2B+ franchise, to fuel results as generics pressure legacy drugs ahead of Q4 earnings.",
    "url": "https://finnhub.io/api/news?id=201eee4a76dd71d58f6c2edd6ba072051a30d268602353be94fef49990373258",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770136740,
      "headline": "Will Reblozyl Shine in Bristol Myers' Fourth-Quarter Results?",
      "id": 138345548,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "BMY leans on fast-growing Reblozyl, now a $2B+ franchise, to fuel results as generics pressure legacy drugs ahead of Q4 earnings.",
      "url": "https://finnhub.io/api/news?id=201eee4a76dd71d58f6c2edd6ba072051a30d268602353be94fef49990373258"
    }
  },
  {
    "ts": null,
    "headline": "MRK Q4 Earnings & Sales Beat Estimates, Stock Down on Weak '26 View",
    "summary": "Merck tops Q4 EPS and sales estimates as Keytruda drives growth, but shares fall in pre-market trading as 2026 guidance disappoints.",
    "url": "https://finnhub.io/api/news?id=c1d016b3901820d6583fcfb61fc8db1923fd78d522832004bc91284dcaffcd7e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770136560,
      "headline": "MRK Q4 Earnings & Sales Beat Estimates, Stock Down on Weak '26 View",
      "id": 138345617,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck tops Q4 EPS and sales estimates as Keytruda drives growth, but shares fall in pre-market trading as 2026 guidance disappoints.",
      "url": "https://finnhub.io/api/news?id=c1d016b3901820d6583fcfb61fc8db1923fd78d522832004bc91284dcaffcd7e"
    }
  },
  {
    "ts": null,
    "headline": "Merck (MRK) Is Up 5.6% After Cautious 2026 Outlook And Ongoing Oncology Investment Plans – What's Changed",
    "summary": "Merck & Co., Inc. reported past fourth-quarter 2025 results with sales of US$16.40 billion and net income of US$2.96 billion, and issued 2026 sales guidance of US$65.50 billion to US$67.00 billion along with earnings expectations that factor in acquisition-related charges and product exclusivity losses. Alongside this guidance, Merck reaffirmed a quarterly dividend of US$0.85 per share and highlighted continued investment in oncology, vaccines, and R&D collaborations to support longer-term...",
    "url": "https://finnhub.io/api/news?id=89d88e89db0c2156ca7f5dafc8f475763bf60d976cb34758be2a31f3ceda82b0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770135244,
      "headline": "Merck (MRK) Is Up 5.6% After Cautious 2026 Outlook And Ongoing Oncology Investment Plans – What's Changed",
      "id": 138344138,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck & Co., Inc. reported past fourth-quarter 2025 results with sales of US$16.40 billion and net income of US$2.96 billion, and issued 2026 sales guidance of US$65.50 billion to US$67.00 billion along with earnings expectations that factor in acquisition-related charges and product exclusivity losses. Alongside this guidance, Merck reaffirmed a quarterly dividend of US$0.85 per share and highlighted continued investment in oncology, vaccines, and R&D collaborations to support longer-term...",
      "url": "https://finnhub.io/api/news?id=89d88e89db0c2156ca7f5dafc8f475763bf60d976cb34758be2a31f3ceda82b0"
    }
  },
  {
    "ts": null,
    "headline": "Merck Stock Gains as Earnings Top Estimates. ‘Momentum Is Building,’ Says CEO.",
    "summary": "Merck  traded higher after the biotechnology giant posted better-than-expected earnings for the fourth quarter, helping investors look past a soft 2026 forecast.  Merck  posted adjusted earnings of $2.04 a share and sales of $16.4 billion, ahead of the profit of $2.01 and revenue of $16.2 billion analysts had projected.  The company pointed to strength in its oncology, respiratory, and cardiometabolic businesses, which was partially offset by weakness in vaccines.",
    "url": "https://finnhub.io/api/news?id=dac8965c5dad5e0ac45118a83b379898dce024fd707ab37a9559e1182ced7ad5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770134460,
      "headline": "Merck Stock Gains as Earnings Top Estimates. ‘Momentum Is Building,’ Says CEO.",
      "id": 138344139,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck  traded higher after the biotechnology giant posted better-than-expected earnings for the fourth quarter, helping investors look past a soft 2026 forecast.  Merck  posted adjusted earnings of $2.04 a share and sales of $16.4 billion, ahead of the profit of $2.01 and revenue of $16.2 billion analysts had projected.  The company pointed to strength in its oncology, respiratory, and cardiometabolic businesses, which was partially offset by weakness in vaccines.",
      "url": "https://finnhub.io/api/news?id=dac8965c5dad5e0ac45118a83b379898dce024fd707ab37a9559e1182ced7ad5"
    }
  },
  {
    "ts": null,
    "headline": "Merck (MRK) Reports Q4 Earnings: What Key Metrics Have to Say",
    "summary": "Although the revenue and EPS for Merck (MRK) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.",
    "url": "https://finnhub.io/api/news?id=a1ad22336fda4b4d7af06ebe4b59f65fe1db4486dd56290fb6d86ea2600fc2b4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770134402,
      "headline": "Merck (MRK) Reports Q4 Earnings: What Key Metrics Have to Say",
      "id": 138344140,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Although the revenue and EPS for Merck (MRK) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.",
      "url": "https://finnhub.io/api/news?id=a1ad22336fda4b4d7af06ebe4b59f65fe1db4486dd56290fb6d86ea2600fc2b4"
    }
  },
  {
    "ts": null,
    "headline": "Market Awaits JOLTS Jobs Report",
    "summary": "Market Awaits JOLTS Jobs Report.",
    "url": "https://finnhub.io/api/news?id=cb5a39d86ad7e4bed95ffa3fc4762ac20a7bf68aac285a0c5a4e0876abda66df",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770134400,
      "headline": "Market Awaits JOLTS Jobs Report",
      "id": 138344141,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Market Awaits JOLTS Jobs Report.",
      "url": "https://finnhub.io/api/news?id=cb5a39d86ad7e4bed95ffa3fc4762ac20a7bf68aac285a0c5a4e0876abda66df"
    }
  },
  {
    "ts": null,
    "headline": "Merck (MRK) Q4 2025 Earnings Call Transcript",
    "summary": "If our underlying assumptions prove inaccurate or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.  Merck & Co., Inc., Rahway, New Jersey, USA undertakes no obligation to publicly update any forward-looking statements.",
    "url": "https://finnhub.io/api/news?id=bbc8e7ca409803ca8447c9f64084c99d16a3bbbd5de87a830c14875353d5d102",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770133222,
      "headline": "Merck (MRK) Q4 2025 Earnings Call Transcript",
      "id": 138342608,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "If our underlying assumptions prove inaccurate or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.  Merck & Co., Inc., Rahway, New Jersey, USA undertakes no obligation to publicly update any forward-looking statements.",
      "url": "https://finnhub.io/api/news?id=bbc8e7ca409803ca8447c9f64084c99d16a3bbbd5de87a830c14875353d5d102"
    }
  },
  {
    "ts": null,
    "headline": "Are Wall Street Analysts Bullish on Moderna Stock?",
    "summary": "While Moderna has outpaced the S&P 500 over the past year, Wall Street analysts maintain a cautious outlook about the stock’s prospects.",
    "url": "https://finnhub.io/api/news?id=f2a3b349b4e897cda602d23e9882ef50603c91c6d5f37e28e0dc7c43d6eb4610",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770133069,
      "headline": "Are Wall Street Analysts Bullish on Moderna Stock?",
      "id": 138345618,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "While Moderna has outpaced the S&P 500 over the past year, Wall Street analysts maintain a cautious outlook about the stock’s prospects.",
      "url": "https://finnhub.io/api/news?id=f2a3b349b4e897cda602d23e9882ef50603c91c6d5f37e28e0dc7c43d6eb4610"
    }
  },
  {
    "ts": null,
    "headline": "Q4 Earnings, JOLTS & a Changing of the Disney Guard",
    "summary": "Disney CEO Bob Iger will step down next month -- not the end of the year, as earlier surmised.",
    "url": "https://finnhub.io/api/news?id=5c737a1b699b4ee77bd51b01cdcdb9e522430d0ad425a678e231536f59044fae",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770132360,
      "headline": "Q4 Earnings, JOLTS & a Changing of the Disney Guard",
      "id": 138344142,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Disney CEO Bob Iger will step down next month -- not the end of the year, as earlier surmised.",
      "url": "https://finnhub.io/api/news?id=5c737a1b699b4ee77bd51b01cdcdb9e522430d0ad425a678e231536f59044fae"
    }
  },
  {
    "ts": null,
    "headline": "Stock Market Today: Dow Steady As Palantir Soars On Earnings; PayPal Plunges (Live Coverage)",
    "summary": "Stock Market Today: The Dow Jones index was steady Tuesday as Palantir surged on earnings. But PayPal stock plunged.",
    "url": "https://finnhub.io/api/news?id=1d9bc7a8211ab83c7d103a7b2b41c589fcadace2ad0a88fe5fa80c76a06ade2a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770125799,
      "headline": "Stock Market Today: Dow Steady As Palantir Soars On Earnings; PayPal Plunges (Live Coverage)",
      "id": 138341583,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Stock Market Today: The Dow Jones index was steady Tuesday as Palantir surged on earnings. But PayPal stock plunged.",
      "url": "https://finnhub.io/api/news?id=1d9bc7a8211ab83c7d103a7b2b41c589fcadace2ad0a88fe5fa80c76a06ade2a"
    }
  },
  {
    "ts": null,
    "headline": "Here's Why Gilead Sciences Stock Surged 21% in a Month",
    "summary": "GILD shares gain traction post Jan. 20 after NEJM data show Trodelvy plus Keytruda cut progression risk 35% in first-line PD-L1+ metastatic TNBC, signaling a new care standard.",
    "url": "https://finnhub.io/api/news?id=cc1116d179a24e39c202e25a799f76a3cca78d58bde0b18f97992ac65af7ce55",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770128820,
      "headline": "Here's Why Gilead Sciences Stock Surged 21% in a Month",
      "id": 138344143,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "GILD shares gain traction post Jan. 20 after NEJM data show Trodelvy plus Keytruda cut progression risk 35% in first-line PD-L1+ metastatic TNBC, signaling a new care standard.",
      "url": "https://finnhub.io/api/news?id=cc1116d179a24e39c202e25a799f76a3cca78d58bde0b18f97992ac65af7ce55"
    }
  },
  {
    "ts": null,
    "headline": "Wall Street Digests Corporate Earnings Amid Government Shutdown, With US Equity Futures Higher Pre-Bell",
    "summary": "US equity futures were higher pre-bell Tuesday as traders digested quarterly earnings amid a partial",
    "url": "https://finnhub.io/api/news?id=7af4778e3db305e9f3f7d31cc06907ce9e72a8713d8ffbd583467df24084c140",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770127633,
      "headline": "Wall Street Digests Corporate Earnings Amid Government Shutdown, With US Equity Futures Higher Pre-Bell",
      "id": 138342568,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "US equity futures were higher pre-bell Tuesday as traders digested quarterly earnings amid a partial",
      "url": "https://finnhub.io/api/news?id=7af4778e3db305e9f3f7d31cc06907ce9e72a8713d8ffbd583467df24084c140"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer: Messy Q4 Earnings Mask An Improving Business",
    "summary": "Pfizer Inc. Buy: market overreacts to Q4 loss and 2026 guidance; oncology-led growth, 102-candidate pipeline, and dividend offer upside. Click for this PFE update.",
    "url": "https://finnhub.io/api/news?id=d35b5f6efcdfd74537a4380fb1cdfc64300a2eb6f057c7f117ef2a0e25c3daf3",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770127379,
      "headline": "Pfizer: Messy Q4 Earnings Mask An Improving Business",
      "id": 138345061,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1372778958/image_1372778958.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Pfizer Inc. Buy: market overreacts to Q4 loss and 2026 guidance; oncology-led growth, 102-candidate pipeline, and dividend offer upside. Click for this PFE update.",
      "url": "https://finnhub.io/api/news?id=d35b5f6efcdfd74537a4380fb1cdfc64300a2eb6f057c7f117ef2a0e25c3daf3"
    }
  },
  {
    "ts": null,
    "headline": "Merck Issues Full-Year Outlook Below Expectations Despite Fourth-Quarter Beat",
    "summary": "Merck (MRK) provided a full-year outlook below Wall Street's estimates on Tuesday, overshadowing the",
    "url": "https://finnhub.io/api/news?id=48f01f3a9fcfdd2058ada0d0741ef9ede3461c0398298409557455926fa170f7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770127159,
      "headline": "Merck Issues Full-Year Outlook Below Expectations Despite Fourth-Quarter Beat",
      "id": 138342611,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck (MRK) provided a full-year outlook below Wall Street's estimates on Tuesday, overshadowing the",
      "url": "https://finnhub.io/api/news?id=48f01f3a9fcfdd2058ada0d0741ef9ede3461c0398298409557455926fa170f7"
    }
  },
  {
    "ts": null,
    "headline": "Merck & Co., Inc. (MRK) Q4 2025 Earnings Call Transcript",
    "summary": "Merck & Co., Inc. (MRK) Q4 2025 Earnings Call Transcript",
    "url": "https://finnhub.io/api/news?id=aef99509d3eca05c1748871fc15572665116476a17ba378cc23295d7563df294",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770125432,
      "headline": "Merck & Co., Inc. (MRK) Q4 2025 Earnings Call Transcript",
      "id": 138344871,
      "image": "",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=aef99509d3eca05c1748871fc15572665116476a17ba378cc23295d7563df294"
    }
  },
  {
    "ts": null,
    "headline": "Merck and Pfizer decline vs the broader market as results released",
    "summary": "The pharma industry is handling big transitions, as highlighted in Merck's and Pfizer's earnings, released Tuesday",
    "url": "https://finnhub.io/api/news?id=ba9f79f6434ff1155a2187d85c1256ef9bbfe8bd6c750cd1c983093ef72793f1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770124780,
      "headline": "Merck and Pfizer decline vs the broader market as results released",
      "id": 138341659,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "The pharma industry is handling big transitions, as highlighted in Merck's and Pfizer's earnings, released Tuesday",
      "url": "https://finnhub.io/api/news?id=ba9f79f6434ff1155a2187d85c1256ef9bbfe8bd6c750cd1c983093ef72793f1"
    }
  },
  {
    "ts": null,
    "headline": "These Stocks Are Today’s Movers: Palantir, Teradyne, Tesla, AMD, NXP Semiconductors, and More",
    "summary": "Stock futures were rising Tuesday as Palantir’s strong earnings injected renewed optimism around the artificial-intelligence trade.  Palantir Technologies  jumped 10% in premarket trading after the company, which sells artificial-intelligence software to manage and analyze large amounts of data, reported better-than expected fourth-quarter adjusted earnings.  Revenue jumped 70% from a year earlier to a record $1.41 billion on strong demand for its AI technology.",
    "url": "https://finnhub.io/api/news?id=05e315ff42909f414aaf1b2be1483a82fec257f9218cec2501d4538edd3a8ce0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770114300,
      "headline": "These Stocks Are Today’s Movers: Palantir, Teradyne, Tesla, AMD, NXP Semiconductors, and More",
      "id": 138340729,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Stock futures were rising Tuesday as Palantir’s strong earnings injected renewed optimism around the artificial-intelligence trade.  Palantir Technologies  jumped 10% in premarket trading after the company, which sells artificial-intelligence software to manage and analyze large amounts of data, reported better-than expected fourth-quarter adjusted earnings.  Revenue jumped 70% from a year earlier to a record $1.41 billion on strong demand for its AI technology.",
      "url": "https://finnhub.io/api/news?id=05e315ff42909f414aaf1b2be1483a82fec257f9218cec2501d4538edd3a8ce0"
    }
  },
  {
    "ts": null,
    "headline": "Merck (MRK) Q4 Earnings and Revenues Beat Estimates",
    "summary": "Merck (MRK) delivered earnings and revenue surprises of +0.62% and +1.33%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?",
    "url": "https://finnhub.io/api/news?id=b527a90efab2910fc1bd4db7f9db4b65c6414decd1b78bab57dc3e9474082d7c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770122402,
      "headline": "Merck (MRK) Q4 Earnings and Revenues Beat Estimates",
      "id": 138342546,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck (MRK) delivered earnings and revenue surprises of +0.62% and +1.33%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?",
      "url": "https://finnhub.io/api/news?id=b527a90efab2910fc1bd4db7f9db4b65c6414decd1b78bab57dc3e9474082d7c"
    }
  },
  {
    "ts": null,
    "headline": "Merck & Co lifts earnings on oncology growth, flags hit to 2026 view",
    "summary": "Merck & Co lifts earnings on oncology growth, flags hit to 2026 view",
    "url": "https://finnhub.io/api/news?id=67b9af239f0a88e5dcbb24729297c0d8565d75316b34c22a27d224df176ba256",
    "source": "Fintel",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770121782,
      "headline": "Merck & Co lifts earnings on oncology growth, flags hit to 2026 view",
      "id": 138341096,
      "image": "",
      "related": "MRK",
      "source": "Fintel",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=67b9af239f0a88e5dcbb24729297c0d8565d75316b34c22a27d224df176ba256"
    }
  },
  {
    "ts": null,
    "headline": "Jim Cramer on Merck & Co.: “I Think It Can Spread Out the Wealth”",
    "summary": "Merck & Co., Inc. (NYSE:MRK) is one of the stocks on Jim Cramer’s recent game plan. Cramer noted that he likes the stock, as he said: Merck has a lot to talk about, namely, some real wins from its bountiful acquisition spree. I like the stock. A little too heavy on Keytruda right now, but […]",
    "url": "https://finnhub.io/api/news?id=fbab22b7afedffce2bfeb6162cdf97d8c79268403ee767307a1f8f32d2d9be3e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770121440,
      "headline": "Jim Cramer on Merck & Co.: “I Think It Can Spread Out the Wealth”",
      "id": 138341661,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck & Co., Inc. (NYSE:MRK) is one of the stocks on Jim Cramer’s recent game plan. Cramer noted that he likes the stock, as he said: Merck has a lot to talk about, namely, some real wins from its bountiful acquisition spree. I like the stock. A little too heavy on Keytruda right now, but […]",
      "url": "https://finnhub.io/api/news?id=fbab22b7afedffce2bfeb6162cdf97d8c79268403ee767307a1f8f32d2d9be3e"
    }
  },
  {
    "ts": null,
    "headline": "Jim Cramer on PepsiCo’s Recent Rally: “Maybe Something’s Going On”",
    "summary": "PepsiCo, Inc. (NASDAQ:PEP) is one of the stocks on Jim Cramer’s recent game plan. Cramer highlighted the company’s snack division struggling due to GLP-1 drugs, as he remarked: Now, Tuesday’s filled with high-profile companies like PepsiCo, Merck, and Pfizer in the morning. I worry about PepsiCo because of its snack division, Frito-Lay. It’s struggling, a […]",
    "url": "https://finnhub.io/api/news?id=8373b07b1aa95d4bd5e8c6df932127c629b16d41c1c9c71921b9b8ba86f7d7bd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770121438,
      "headline": "Jim Cramer on PepsiCo’s Recent Rally: “Maybe Something’s Going On”",
      "id": 138341662,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "PepsiCo, Inc. (NASDAQ:PEP) is one of the stocks on Jim Cramer’s recent game plan. Cramer highlighted the company’s snack division struggling due to GLP-1 drugs, as he remarked: Now, Tuesday’s filled with high-profile companies like PepsiCo, Merck, and Pfizer in the morning. I worry about PepsiCo because of its snack division, Frito-Lay. It’s struggling, a […]",
      "url": "https://finnhub.io/api/news?id=8373b07b1aa95d4bd5e8c6df932127c629b16d41c1c9c71921b9b8ba86f7d7bd"
    }
  },
  {
    "ts": null,
    "headline": "Merck Earnings Top Estimates. Why the Stock Is Falling.",
    "summary": "Merck  stock declined Tuesday even after the biotechnology giant posted better-than-expected earnings for the fourth quarter.  Merck posted adjusted earnings of $2.04 a share and sales of $16.4 billion, ahead of the profit of $2.01 and revenue of $16.2 billion analysts had projected.  As they did in the prior quarter, sales of Keytruda, Merck’s blockbuster cancer immunotherapy drug, continued to see growth, rising 7% to $8.4 billion.",
    "url": "https://finnhub.io/api/news?id=0875bfc9c785baf20742ead877e8f320e3549017c9b972848dd5579ba853a256",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770121020,
      "headline": "Merck Earnings Top Estimates. Why the Stock Is Falling.",
      "id": 138341663,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck  stock declined Tuesday even after the biotechnology giant posted better-than-expected earnings for the fourth quarter.  Merck posted adjusted earnings of $2.04 a share and sales of $16.4 billion, ahead of the profit of $2.01 and revenue of $16.2 billion analysts had projected.  As they did in the prior quarter, sales of Keytruda, Merck’s blockbuster cancer immunotherapy drug, continued to see growth, rising 7% to $8.4 billion.",
      "url": "https://finnhub.io/api/news?id=0875bfc9c785baf20742ead877e8f320e3549017c9b972848dd5579ba853a256"
    }
  },
  {
    "ts": null,
    "headline": "Stocks Mostly Rise Pre-Bell as Investors Await Latest Round of Corporate Earnings",
    "summary": "US equity futures were mostly pointing higher on Tuesday as traders await a fresh batch of corporate",
    "url": "https://finnhub.io/api/news?id=a4b55d3dfcdc527e15b9028fa2e3c93b8426e666df2a78822f6203e6d77b68b3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770120977,
      "headline": "Stocks Mostly Rise Pre-Bell as Investors Await Latest Round of Corporate Earnings",
      "id": 138341612,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "US equity futures were mostly pointing higher on Tuesday as traders await a fresh batch of corporate",
      "url": "https://finnhub.io/api/news?id=a4b55d3dfcdc527e15b9028fa2e3c93b8426e666df2a78822f6203e6d77b68b3"
    }
  },
  {
    "ts": null,
    "headline": "Merck shares fall as 2026 guidance disappoints despite solid Q4 results",
    "summary": "Investing.com -- Merck & Co. (NYSE:MRK) shares have dropped 1.6% premarket on Tuesday after the pharmaceutical giant issued 2026 guidance below analyst expectations, overshadowing solid fourth-quarter results that met earnings forecasts and slightly exceeded revenue estimates.",
    "url": "https://finnhub.io/api/news?id=943edffc7a7e7f4d39edbdc7f8bf88180fde520a199ac1e0c594fbc906fdb6db",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770120694,
      "headline": "Merck shares fall as 2026 guidance disappoints despite solid Q4 results",
      "id": 138341665,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Investing.com -- Merck & Co. (NYSE:MRK) shares have dropped 1.6% premarket on Tuesday after the pharmaceutical giant issued 2026 guidance below analyst expectations, overshadowing solid fourth-quarter results that met earnings forecasts and slightly exceeded revenue estimates.",
      "url": "https://finnhub.io/api/news?id=943edffc7a7e7f4d39edbdc7f8bf88180fde520a199ac1e0c594fbc906fdb6db"
    }
  },
  {
    "ts": null,
    "headline": "Why Pfizer shares are under pressure despite a Q4 earnings beat",
    "summary": "Evan Seigerman, head of healthcare research at BMO Capital Markets, joins 'Money Movers' to discuss Pfizer and Merck's latest earnings results, market themes, and more.",
    "url": "https://finnhub.io/api/news?id=8b322d6be346bed0daa1265a2a42650137e4d212831b003817d8bb3c45bb9ff8",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770120400,
      "headline": "Why Pfizer shares are under pressure despite a Q4 earnings beat",
      "id": 138343646,
      "image": "https://image.cnbcfm.com/api/v1/image/108260802-17701374661770137463-43831211275-1080pnbcnews.jpg?v=1770137465&w=1920&h=1080",
      "related": "MRK",
      "source": "CNBC",
      "summary": "Evan Seigerman, head of healthcare research at BMO Capital Markets, joins 'Money Movers' to discuss Pfizer and Merck's latest earnings results, market themes, and more.",
      "url": "https://finnhub.io/api/news?id=8b322d6be346bed0daa1265a2a42650137e4d212831b003817d8bb3c45bb9ff8"
    }
  },
  {
    "ts": null,
    "headline": "Merck’s (NYSE:MRK) Q4 CY2025 Sales Beat Estimates",
    "summary": "Global pharmaceutical company Merck (NYSE:MRK) beat Wall Street’s revenue expectations in Q4 CY2025, with sales up 5% year on year to $16.4 billion. On the other hand, the company’s full-year revenue guidance of $66.25 billion at the midpoint came in 2% below analysts’ estimates. Its non-GAAP profit of $2.04 per share was 1.5% above analysts’ consensus estimates.",
    "url": "https://finnhub.io/api/news?id=f266e8d34e306921289a99a0ebb3cf2761370efe8680b06c55fdae2c83bcf3ee",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770119313,
      "headline": "Merck’s (NYSE:MRK) Q4 CY2025 Sales Beat Estimates",
      "id": 138341666,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Global pharmaceutical company Merck (NYSE:MRK) beat Wall Street’s revenue expectations in Q4 CY2025, with sales up 5% year on year to $16.4 billion. On the other hand, the company’s full-year revenue guidance of $66.25 billion at the midpoint came in 2% below analysts’ estimates. Its non-GAAP profit of $2.04 per share was 1.5% above analysts’ consensus estimates.",
      "url": "https://finnhub.io/api/news?id=f266e8d34e306921289a99a0ebb3cf2761370efe8680b06c55fdae2c83bcf3ee"
    }
  },
  {
    "ts": null,
    "headline": "Merck forecasts 2026 sales below estimates on patent losses",
    "summary": "By Michael Erman Feb 3 (Reuters) - Merck & Co on Tuesday forecast 2026 sales and profits below Wall Street estimates as the loss of patent exclusivity on diabetes drug Januvia and other medicines will",
    "url": "https://finnhub.io/api/news?id=ecc244decd7a8bfee56e793d7e7e0d6778d53574500f0d39146c11696f12198a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770118820,
      "headline": "Merck forecasts 2026 sales below estimates on patent losses",
      "id": 138340764,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "By Michael Erman Feb 3 (Reuters) - Merck & Co on Tuesday forecast 2026 sales and profits below Wall Street estimates as the loss of patent exclusivity on diabetes drug Januvia and other medicines will",
      "url": "https://finnhub.io/api/news?id=ecc244decd7a8bfee56e793d7e7e0d6778d53574500f0d39146c11696f12198a"
    }
  },
  {
    "ts": null,
    "headline": "Merck: Q4 Earnings Snapshot",
    "summary": "RAHWAY, N.J. (AP) — Merck & Co. (MRK) on Tuesday reported fourth-quarter profit of $2.96 billion. On a per-share basis, the Rahway, New Jersey-based company said it had net income of $1.19. Earnings, adjusted for restructuring costs and costs related to mergers and acquisitions, came to $2.04 per share.",
    "url": "https://finnhub.io/api/news?id=e9c2acadf53c1cafb0bb30b913076da1ec541210cdf45f994dc393bedc1b5e36",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770118819,
      "headline": "Merck: Q4 Earnings Snapshot",
      "id": 138340765,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "RAHWAY, N.J. (AP) — Merck & Co. (MRK) on Tuesday reported fourth-quarter profit of $2.96 billion. On a per-share basis, the Rahway, New Jersey-based company said it had net income of $1.19. Earnings, adjusted for restructuring costs and costs related to mergers and acquisitions, came to $2.04 per share.",
      "url": "https://finnhub.io/api/news?id=e9c2acadf53c1cafb0bb30b913076da1ec541210cdf45f994dc393bedc1b5e36"
    }
  },
  {
    "ts": null,
    "headline": "Merck Expects Slower Earnings Growth As It Spends on Acquisitions",
    "summary": "Merck recorded higher revenue in its fourth quarter, but expects earnings growth to slow as it ramps up acquisitions.",
    "url": "https://finnhub.io/api/news?id=822a082c14023b10be91a24b5243ca17f00ccf390877c1f053f37998c2b195c0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770118680,
      "headline": "Merck Expects Slower Earnings Growth As It Spends on Acquisitions",
      "id": 138341667,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck recorded higher revenue in its fourth quarter, but expects earnings growth to slow as it ramps up acquisitions.",
      "url": "https://finnhub.io/api/news?id=822a082c14023b10be91a24b5243ca17f00ccf390877c1f053f37998c2b195c0"
    }
  },
  {
    "ts": null,
    "headline": "Dow Jones Giant Merck Crushes Fourth-Quarter Views. But Guidance Could Shake Shares.",
    "summary": "Merck quashed fourth-quarter expectations Tuesday, but the Dow Jones health giant issued lackluster expectations for 2026.",
    "url": "https://finnhub.io/api/news?id=8566055234992d68e6ad2231b68b028417bfaf34b22d466a09f792547b457a25",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770118271,
      "headline": "Dow Jones Giant Merck Crushes Fourth-Quarter Views. But Guidance Could Shake Shares.",
      "id": 138340766,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck quashed fourth-quarter expectations Tuesday, but the Dow Jones health giant issued lackluster expectations for 2026.",
      "url": "https://finnhub.io/api/news?id=8566055234992d68e6ad2231b68b028417bfaf34b22d466a09f792547b457a25"
    }
  },
  {
    "ts": null,
    "headline": "Merck & Co., Inc., Rahway, N.J., USA Announces Fourth-Quarter and Full-Year 2025 Financial Results; Highlights Progress Advancing Broad, Diverse Pipeline",
    "summary": "RAHWAY, N.J., February 03, 2026--Merck & Co., Inc., Rahway, N.J., USA Announces Fourth-Quarter and Full-Year 2025 Financial Results",
    "url": "https://finnhub.io/api/news?id=fb71cb503faa5192e4ddb1ecc5346cd7cfc6406fc849d7e3889b8b0eec2f8f34",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770118200,
      "headline": "Merck & Co., Inc., Rahway, N.J., USA Announces Fourth-Quarter and Full-Year 2025 Financial Results; Highlights Progress Advancing Broad, Diverse Pipeline",
      "id": 138340767,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "RAHWAY, N.J., February 03, 2026--Merck & Co., Inc., Rahway, N.J., USA Announces Fourth-Quarter and Full-Year 2025 Financial Results",
      "url": "https://finnhub.io/api/news?id=fb71cb503faa5192e4ddb1ecc5346cd7cfc6406fc849d7e3889b8b0eec2f8f34"
    }
  },
  {
    "ts": null,
    "headline": "Tech Bulls Rule Equities Pre-Bell; Asia Surges, Europe Gains",
    "summary": "Wall Street futures pointed moderately higher pre-bell Tuesday, following record-breaking rallies ov",
    "url": "https://finnhub.io/api/news?id=51b49704d7ea7ffbddbd1ebfa51c0196c13b7d823b3098096d13e996a2b29c33",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770117643,
      "headline": "Tech Bulls Rule Equities Pre-Bell; Asia Surges, Europe Gains",
      "id": 138340741,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Wall Street futures pointed moderately higher pre-bell Tuesday, following record-breaking rallies ov",
      "url": "https://finnhub.io/api/news?id=51b49704d7ea7ffbddbd1ebfa51c0196c13b7d823b3098096d13e996a2b29c33"
    }
  },
  {
    "ts": null,
    "headline": "Where is Merck & Co. (MRK) Headed According to Wall Street?",
    "summary": "Merck & Co., Inc. (NYSE:MRK) is one of the best long term low volatility stocks to invest in. Merck & Co., Inc. (NYSE:MRK) announced on January 27 that its Board of Directors declared a quarterly dividend of $0.85 per share of the company’s common stock for fiscal Q2 2026. Management reported that the payment will […]",
    "url": "https://finnhub.io/api/news?id=6dcabf9a7802288d94cee14c4ef8094270a295d81b6ed8c083eca5a775e3c78d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770111264,
      "headline": "Where is Merck & Co. (MRK) Headed According to Wall Street?",
      "id": 138340052,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck & Co., Inc. (NYSE:MRK) is one of the best long term low volatility stocks to invest in. Merck & Co., Inc. (NYSE:MRK) announced on January 27 that its Board of Directors declared a quarterly dividend of $0.85 per share of the company’s common stock for fiscal Q2 2026. Management reported that the payment will […]",
      "url": "https://finnhub.io/api/news?id=6dcabf9a7802288d94cee14c4ef8094270a295d81b6ed8c083eca5a775e3c78d"
    }
  },
  {
    "ts": null,
    "headline": "Stocks to Watch Tuesday: Palantir, Teradyne, AMD",
    "summary": "↗️ Palantir (PLTR): The data company reported higher-than-expected earnings, as strong demand for its AI technology fueled another quarter of record revenue. Palantir stock jumped 5% in offhours trading.",
    "url": "https://finnhub.io/api/news?id=bbb73c04ae117f7d0e8bac7e16b4b5afa0cb17be2bc8db6eb2f78e47c9014699",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770107948,
      "headline": "Stocks to Watch Tuesday: Palantir, Teradyne, AMD",
      "id": 138340028,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "↗️ Palantir (PLTR): The data company reported higher-than-expected earnings, as strong demand for its AI technology fueled another quarter of record revenue. Palantir stock jumped 5% in offhours trading.",
      "url": "https://finnhub.io/api/news?id=bbb73c04ae117f7d0e8bac7e16b4b5afa0cb17be2bc8db6eb2f78e47c9014699"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer, Merk report Q4 results: Citi's Geoff Meacham on key takeaways",
    "summary": "Geoff Meacham, Citi Research head of U.S. pharmaceuticals and biotechnology, joins 'Squawk Box' to break down the quarterly earnings results of Pfizer and Merck.",
    "url": "https://finnhub.io/api/news?id=60b6d1c420895350e8a898097fdcee889bc3b42fc09a26986ca92b62e75da697",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770106900,
      "headline": "Pfizer, Merk report Q4 results: Citi's Geoff Meacham on key takeaways",
      "id": 138343647,
      "image": "https://image.cnbcfm.com/api/v1/image/108260670-17701243561770124353-43828552119-1080pnbcnews.jpg?v=1770124355&w=1920&h=1080",
      "related": "MRK",
      "source": "CNBC",
      "summary": "Geoff Meacham, Citi Research head of U.S. pharmaceuticals and biotechnology, joins 'Squawk Box' to break down the quarterly earnings results of Pfizer and Merck.",
      "url": "https://finnhub.io/api/news?id=60b6d1c420895350e8a898097fdcee889bc3b42fc09a26986ca92b62e75da697"
    }
  },
  {
    "ts": null,
    "headline": "The xAI-SpaceX merger, Palantir earnings, China's frowning horses and more in Morning Squawk",
    "summary": "Here are five key things investors need to know to start the trading day.",
    "url": "https://finnhub.io/api/news?id=6368705e46c91a048d8a8e14b39b2c8503bb3343fc3e873fcccc1b1bd0b9da69",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770106360,
      "headline": "The xAI-SpaceX merger, Palantir earnings, China's frowning horses and more in Morning Squawk",
      "id": 138343473,
      "image": "https://image.cnbcfm.com/api/v1/image/108255762-17690962602026-01-22t153714z_1035611969_rc2f6jatc4xw_rtrmadp_0_davos-meeting.jpeg?v=1769096274&w=1920&h=1080",
      "related": "MRK",
      "source": "CNBC",
      "summary": "Here are five key things investors need to know to start the trading day.",
      "url": "https://finnhub.io/api/news?id=6368705e46c91a048d8a8e14b39b2c8503bb3343fc3e873fcccc1b1bd0b9da69"
    }
  },
  {
    "ts": null,
    "headline": "Big Tech and Pharma Earnings: What to Watch This Week",
    "summary": "Earnings season marches on. Two more Magnificent Seven tech companies—Alphabet and Amazon—will report, following on the heels of disappointing results from Microsoft that helped send software stocks tumbling last week.",
    "url": "https://finnhub.io/api/news?id=9aa613f24a7650ac7b730d72057e5922be4de4b5ab97ebd182e8d85bdb78a6bc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770105706,
      "headline": "Big Tech and Pharma Earnings: What to Watch This Week",
      "id": 138340001,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Earnings season marches on. Two more Magnificent Seven tech companies—Alphabet and Amazon—will report, following on the heels of disappointing results from Microsoft that helped send software stocks tumbling last week.",
      "url": "https://finnhub.io/api/news?id=9aa613f24a7650ac7b730d72057e5922be4de4b5ab97ebd182e8d85bdb78a6bc"
    }
  },
  {
    "ts": null,
    "headline": "Snowflake Makes Enterprise Data AI-Ready With Snowflake Postgres and Advanced Innovations for Open Data Interoperability",
    "summary": "LONDON, February 03, 2026--Snowflake (NYSE: SNOW), the AI Data Cloud company, today announced advancements that make data AI-ready by design, allowing enterprises to rely on data that is continuously available, usable, and governed as AI transitions from experimentation into real-world production systems. With new enhancements to Snowflake Postgres (generally available soon), the world’s most popular database1 now runs natively in the AI Data Cloud so enterprises can consolidate their transactio",
    "url": "https://finnhub.io/api/news?id=f7d025b3aad4669594ab2bd73e6a63b78889ebd9d33e12a6fabe2ff2a48520d9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770105660,
      "headline": "Snowflake Makes Enterprise Data AI-Ready With Snowflake Postgres and Advanced Innovations for Open Data Interoperability",
      "id": 138340055,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "LONDON, February 03, 2026--Snowflake (NYSE: SNOW), the AI Data Cloud company, today announced advancements that make data AI-ready by design, allowing enterprises to rely on data that is continuously available, usable, and governed as AI transitions from experimentation into real-world production systems. With new enhancements to Snowflake Postgres (generally available soon), the world’s most popular database1 now runs natively in the AI Data Cloud so enterprises can consolidate their transactio",
      "url": "https://finnhub.io/api/news?id=f7d025b3aad4669594ab2bd73e6a63b78889ebd9d33e12a6fabe2ff2a48520d9"
    }
  },
  {
    "ts": null,
    "headline": "Stocks making the biggest moves premarket: Palantir Technologies, Merck, Pfizer & more",
    "summary": "These are the stocks posting the largest moves in early trading.",
    "url": "https://finnhub.io/api/news?id=93b8f976d9a2241660827621db63fb76a4411cbc275570ea4d44a48180172444",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770103268,
      "headline": "Stocks making the biggest moves premarket: Palantir Technologies, Merck, Pfizer & more",
      "id": 138343620,
      "image": "https://image.cnbcfm.com/api/v1/image/108241417-1765569784249-gettyimages-2228106182-raa-palantir250806_npd31.jpeg?v=1770120724&w=1920&h=1080",
      "related": "MRK",
      "source": "CNBC",
      "summary": "These are the stocks posting the largest moves in early trading. ",
      "url": "https://finnhub.io/api/news?id=93b8f976d9a2241660827621db63fb76a4411cbc275570ea4d44a48180172444"
    }
  },
  {
    "ts": null,
    "headline": "Merck tops quarterly estimates, posts modest 2026 guidance as generic competition looms",
    "summary": "Merck posted a modest 2026 outlook that fell short of estimates, as it prepares for some drugs to go off patent later this year and face generic competition.",
    "url": "https://finnhub.io/api/news?id=4e40683655502f855c615e7680286d21db2c2cab60066561e0f019278f00d527",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770100319,
      "headline": "Merck tops quarterly estimates, posts modest 2026 guidance as generic competition looms",
      "id": 138343650,
      "image": "https://image.cnbcfm.com/api/v1/image/108250093-17678956902026-01-08t180322z_237136326_rc28ldawa07r_rtrmadp_0_usa-vaccines-hpv.jpeg?v=1767895707&w=1920&h=1080",
      "related": "MRK",
      "source": "CNBC",
      "summary": "Merck posted a modest 2026 outlook that fell short of estimates, as it prepares for some drugs to go off patent later this year and face generic competition.",
      "url": "https://finnhub.io/api/news?id=4e40683655502f855c615e7680286d21db2c2cab60066561e0f019278f00d527"
    }
  },
  {
    "ts": null,
    "headline": "AMD earnings, Netflix-Warner Bros. hearing: What to Watch",
    "summary": "Market Domination Overtime Host Josh Lipton previews several of the biggest stories to come tomorrow, Tuesday, February 3, including earnings results from companies like Advanced Micro Devices (AMD), Chipotle Mexican Grill (CMG), Pfizer (PFE), and Merck (MRK), and the Senate hearing on Netflix's (NFLX) proposed bid to acquire Warner Bros. Discovery (WBD). To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime.",
    "url": "https://finnhub.io/api/news?id=4ee5d7b830f8532018efe43aa21a2c2c8099f91e6a26d7cd230d9a1df55a74d4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770076800,
      "headline": "AMD earnings, Netflix-Warner Bros. hearing: What to Watch",
      "id": 138337318,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Market Domination Overtime Host Josh Lipton previews several of the biggest stories to come tomorrow, Tuesday, February 3, including earnings results from companies like Advanced Micro Devices (AMD), Chipotle Mexican Grill (CMG), Pfizer (PFE), and Merck (MRK), and the Senate hearing on Netflix's (NFLX) proposed bid to acquire Warner Bros. Discovery (WBD). To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime.",
      "url": "https://finnhub.io/api/news?id=4ee5d7b830f8532018efe43aa21a2c2c8099f91e6a26d7cd230d9a1df55a74d4"
    }
  }
]